| Drug ID: | Drug180 |
|---|---|
| Drug Name: | Zasocitinib |
| CID: | 137441492 |
| DrugBank ID: | DB19278 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT06254950, , NCT06233461, , NCT06764615 |
| Molecular Formula: | C23H24N8O3 |
| Molecular Weight: | 460.5 g/mol |
| Isomeric SMILES: | CNC1=CC(=NC2=C(C=NN12)C(=O)N[C@@H]3CC[C@H]3OC)NC4=CC=CN(C4=O)C5=CC=CC=N5 |
| Synonyms: | 2272904-53-5; N-((1R,2R)-2-Methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridin]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo(1(2H),2'-bipyridin)-3-yl)amino)-pyrazolo(1,5-a)pyrimidine-3-carboxamide; N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-(1,2'-bipyridin)-3-yl)amino)pyrazolo(1,5-a)pyrimidine-3-carboxamide; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5-a]pyrimidine-3-carboxamide; 957-394-0; 960-464-3; Zasocitinib; NDI-034858; TAK-279 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1297 | 137441492 | N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5-a]pyrimidine-3-carboxamide | 7297 | TYK2 | Homo sapiens (human) | Inhibition | |
| dt1298 | 137441492 | N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5-a]pyrimidine-3-carboxamide | 7297 | TYK2 | Homo sapiens (human) | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06764615 | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) | PHASE2 | NOT_YET_RECRUITING | Takeda | Crohn's Disease|Ulcerative Colitis | DRUG: Zasocitinib | Details |
| NCT06254950 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis | PHASE2 | RECRUITING | Takeda | Ulcerative Colitis | DRUG: TAK-279|DRUG: Placebo | Details |
| NCT06233461 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | PHASE2 | RECRUITING | Takeda | Crohn's Disease | DRUG: TAK-279|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations